Short Interest in LAVA Therapeutics (NASDAQ:LVTX) Drops By 22.5%

LAVA Therapeutics (NASDAQ:LVTX) was the recipient of a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 45,500 shares, a decline of 22.5% from the December 15th total of 58,700 shares. Approximately 0.3% of the company’s shares are sold short. Based on an average daily trading volume, of 112,000 shares, the short-interest ratio is currently 0.4 days.

LAVA Therapeutics Stock Performance

LAVA Therapeutics stock traded up $0.00 during trading hours on Friday, hitting $0.94. 14,757 shares of the stock traded hands, compared to its average volume of 123,351. The firm’s 50-day moving average price is $1.31 and its two-hundred day moving average price is $1.64. LAVA Therapeutics has a one year low of $0.88 and a one year high of $6.47.

Institutional Trading of LAVA Therapeutics

Large investors have recently bought and sold shares of the company. XTX Topco Ltd bought a new stake in LAVA Therapeutics during the 2nd quarter valued at approximately $55,000. Virtu Financial LLC bought a new stake in LAVA Therapeutics during the 3rd quarter valued at approximately $32,000. Finally, Pathway Financial Advisors LLC boosted its position in LAVA Therapeutics by 70.8% during the 3rd quarter. Pathway Financial Advisors LLC now owns 102,500 shares of the company’s stock valued at $170,000 after acquiring an additional 42,500 shares in the last quarter.

Analyst Upgrades and Downgrades

LVTX has been the topic of several analyst reports. JMP Securities reiterated a “market perform” rating and issued a $6.00 price objective on shares of LAVA Therapeutics in a report on Wednesday, December 11th. Leerink Partnrs downgraded LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th. Citizens Jmp downgraded LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 11th. HC Wainwright reduced their price target on LAVA Therapeutics from $6.00 to $2.00 and set a “buy” rating on the stock in a report on Friday, December 20th. Finally, Leerink Partners restated a “market perform” rating and set a $2.00 price target (down previously from $11.00) on shares of LAVA Therapeutics in a report on Thursday, December 12th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, LAVA Therapeutics currently has a consensus rating of “Hold” and an average target price of $3.33.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.